Compulsory Licensing and Interest of the Inventor

-

"Most patented cancer drugs cost $5,000-6,000 a month. How many patients in India, where there is no public insurance facility, can afford these prices?"


According to section 84 of the Indian Patents Act, 1970, a Compulsory License (CL) can be issued if the patented drug is unavailable, unaffordable or not supplied properly. With Compulsory License domestic companies can manufacture and market generic versions, paying a royalty to the patent holder company

Last year, Hyderabad-based Natco Pharma had won the first ever CL to manufacture its generic version of Bayer's patent-protected anti-cancer drug, Nexavar. With the licence, Natco sold the drug at Rs 8,880 for a pack of 120 tablets, a month's therapy, as against Rs 2.8 lakh, the cost at which Bayer sells Nexavar.

Recently, Government's decision to issue compulsory licences (CLs) for three more patented cancer drugs has joggled the multinational pharmaceutical companies. CLs are being issued for Trastuzumab (or Herceptin, used for treating breast cancer), Ixabepilone (used for chemotherapy in breast cancer treatment) and Dasatinib (or Sprycel, for leukaemia). These cost an average of $3,000-4,500 (Rs 1.64-2.45 lakh) for a month's treatment. Natco is pricing Dasatinib at Rs 9,000 for a month, as compared to BMS’ Rs 1 lakh for a month's treatment. 

Issuing CLs is a matter of concern. CLs cannot solve India’s larger problems regarding access to medicines and healthcare. A pharmaceutical company invests millions of dollars in the development of a new drug. In the absence of these investments and the resulting research and development, there would be no generic medicines for the world’s patients. The research-based pharmaceutical industry fully supports the objective of improving access to innovative medicines but the responsibility to promote development of new drugs lies with all countries, not solely those in the developed world. 

There are access programs by MNCs for medicines which, very often, bring down the prices significantly." Novartis's cancer drug, Glivec, was given free for 16,000 patients in India, claimed to be about 95 per cent of the patients, through The Glivec International Patient Assistance Program (GIPAP). In March, Roche had given a manufacturing and marketing license for Herceptin to Pune-based Emcure Pharma. Herceptin is priced between $3,000 and $4,500 for a month's treatment.

Though issuing CLs is a welcome move but considering the investments of the pharma company and years of research in developing a novel drug makes us think how far the the CLs protect the interest of the inventor??




Comments

  1. Tanveer Verma19 January 2013 at 13:38

    good work dude.... keep writing...

    ReplyDelete
  2. Unknown15 December 2015 at 18:03

    I have not understood all points.. But what i understood that is good!! Good Work Brother!!

    ReplyDelete

Post a Comment

Popular posts from this blog

Starbucks vs. SardarBuksh

-
Image
Branding your brand does not and must not mean that you copy somebody else's brand name and get a free ride upon their good will.  Trademark law is very clear in this aspect while keeping two most essential pre-requisites before registering a trademark as - 1. Trademark has to be distinctive; 2. Trademark must not be descriptive. Lot many brand owners make mistakes in understanding the concept of distinctiveness and start using brand names which are similar to the already existing trademarks which are famous. Making minor changes here and there either in spellings or color combinations or finding a rhyming words to the existing trademarks does not yield distinctiveness to your brand name. Some of the brand owners knowingly make use of such deceptively similar marks and then get sued.  In one of such interesting cases in Delhi High Court, the Court has ruled in favor of Starbucks who filed a case against a local coffee shop chain SardarBuksh for copying word mark a
Read more

Trade Marks and U(nu)sual Misunderstandings

-
Trade Marks registration process in India has seen enormous changes in past 2-3 years. The number of Forms have been reduced from 64 to 8. The examination time has reduced from 2 years to 5 working days - believe it or not but its true and one of the fastest all over the world!   However, the change in law or rules has not impacted some common misconceptions that are prevalent among business owners about the Trade Marks. Thought it would be good to address them here: 1. I don't need to perform search..My Trade Mark is Original in toto Applicants commonly believe that the trade name they thought is distinctive enough and don't see any need to get a search done or to get an opinion from a practitioner. Let me say something unpleasant that the name you want to trademark probably isn’t as original as you think it is, at least not in the eyes of the Trade Marks Registry. Every year, thousands of trademark applications are rejected without refunds because they too closely resembl
Read more

The Jurisdiction Saga on the interplay of the Design Act, 2000 and the Commercial Courts Act, 2015

-
In a very lucid judgment in the case of S.D. Containers vs. Mold-tek Packaging Limited (Civil Appeal No. 3695 of 2020), the Supreme Court of India decided the matter clearing the air of doubt on the interplay of the Design Act, 2000 and the Commercial Courts Act, 2015. Relevant facts on background of the case -  Mold-tek Packaging Limited (hereinafter Plaintiff/Respondent), a manufacturer and seller of plastic packaging material who obtained design registration for its container's lids, jars etc. in 2015 and 2017. In late 2019, the Plaintiff/Respondent came to know about S.D. Containers (hereinafter Defendant/Appellant) who allegedly infringed design of the Plaintiff/Respondent. The Plaintiff/Respondent filed a civil suit before the Commercial Court at Indore seeking permanent injunction against the Defendant/Appellant from copying and using the design of the Plaintiff/Respondent as described in Design Application No. 299039 and 299041 for the containers and lids, respectively. The
Read more